Dopavision

Dopavision is a German digital therapeutics and medical device company headquartered in Berlin. It is developing MyopiaX, a first-in-class, non-invasive therapy that uses selective ocular light stimulation delivered through consumer electronics to slow the progression of myopia (nearsightedness) in children and adolescents. The company describes its mission as bringing a new perspective to eye care by combining selective ocular light stimulation with accessible consumer electronics to non-invasively activate the eye's innate signaling pathways. MyopiaX targets the eye's blind spot with patented light stimulation designed to engage the innate mechanisms that regulate eye growth. The approach is intended to be interactive and child-friendly, integrating into daily routines. Dopavision has investigated MyopiaX in a multicenter, randomized controlled clinical trial (NCT04967287) to evaluate safety, tolerability, and signals of clinical effect on myopia progression in children. Completion of the MyopiaX-1 proof-of-concept trial is described by the company as a crucial step toward providing a safe, non-invasive therapeutic alternative. The company frames its work against a global myopia crisis, noting that myopia is projected to affect nearly 50% of the global population by 2050. Progressive myopia is characterized by worsening distance vision, often due to continuous elongation of the eyeball. Dopavision's team is multidisciplinary, with expertise in biopharmaceuticals, neurosciences, ophthalmology, and health technologies. Its office is located in the heart of Berlin. The founder is Dr. Hamed Bahmani, and the management team includes CEO Dr. Mark Wuttke and CTO Dr. Andreas Balser.

Dopavision was founded by Dr. Hamed Bahmani, who combines expertise in neuroscience, vision sciences, and engineering. The company is headquartered in Berlin, Germany, where its office is located in the heart of the city. It was established to develop breakthrough healthcare solutions that are accessible and designed for everyday life, with a focus on eye care. The company's lead program, MyopiaX, is a transformative approach that aims to slow the progression of myopia in children and adolescents. MyopiaX administers patented, first-in-class selective ocular light stimulation targeting the eye's blind spot, non-invasively engaging the innate mechanisms regulating eye growth. By using consumer electronics, MyopiaX aims to offer an interactive, child-friendly approach designed to integrate seamlessly into daily routines. MyopiaX was investigated in a multicenter, randomized controlled clinical trial (NCT04967287) to evaluate its safety, tolerability, and signals of clinical effect on myopia progression in children. The completion of the MyopiaX-1 proof-of-concept trial marks a crucial step towards Dopavision's mission of providing a safe, non-invasive therapeutic alternative to slow the progression of myopia. The company frames its work against the global myopia crisis, noting that myopia is projected to impact nearly 50% of the global population by 2050. Progressive myopia is marked by a worsening ability to see distant objects clearly, often due to the continuous elongation of the eyeball, causing images to focus in front of the retina. Dopavision's multidisciplinary team has expertise in biopharmaceuticals, neurosciences, ophthalmology, and health technologies.

• Founding of Dopavision by Dr. Hamed Bahmani

• Investigation of MyopiaX in multicenter, randomized controlled clinical trial (NCT04967287)

• Completion of MyopiaX-1 proof-of-concept trial

Developer of non-invasive, light-based digital therapeutics for eye care, focused on slowing myopia progression in children using consumer electronics.

• MyopiaX

  A non-invasive therapy using patented selective ocular light stimulation targeting the eye's blind spot to slow myopia progression in children and adolescents.

1. 1Dopavisiondopavision.com
2. 2Our Team | Dopavision - Experts in Research and Innovationdopavision.com
3. 3Dopavision (Germany)wikidata.org